Comment on: "UGT2B17 modifies drug response in chronic lymphocytic leukaemia"

Br J Cancer. 2020 Oct;123(8):1345-1346. doi: 10.1038/s41416-020-1005-5. Epub 2020 Jul 24.

Authors

Spyros I Papamichos¹, Christof Jungbauer²

Affiliations

¹ Blood Service for Vienna, Lower Austria and Burgenland, Austrian Red Cross, Vienna, Austria. spyros.papamichos@roteskreuz.at.
² Blood Service for Vienna, Lower Austria and Burgenland, Austrian Red Cross, Vienna, Austria.

No abstract available

Publication types

Letter
Comment

MeSH terms

Glucuronosyltransferase
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Minor Histocompatibility Antigens
Pharmaceutical Preparations*
Pyrazoles
Pyrimidines

Substances

Minor Histocompatibility Antigens
Pharmaceutical Preparations
Pyrazoles
Pyrimidines
Glucuronosyltransferase
UGT2B17 protein, human